June 29, 2021 7:31am

Smooth out some new highs by cutting some positions for profit before it’s taken from your portfolio

Pre-open indications: 1 BUY: IONS; 5 SELLs: ALNY, VCEL, EDIT, CRSP, NTLA; 2 Maintain SELL: BSTG, CLLS

My version of the morning’s “indications” is about what you need to know; it’s what could happen or materialize after the opening and what might happen during the session

Subscription is coming in July, it’s not conscription but, an offer to join our collective of like-minded investors!  

Dow futures are UP +0.15% (+51 points), S&P futures are DOWN -0.01% ( -1 point) and NASDAQ futures are DOWN -0.07% (-11 points)

 

U.S. stock index futures are fluctuating up and down on Tuesday pointing to a flat open,

European stocks were up

Asia-Pacific stocks declined, with Japan’s Nikkei 225 and the Shanghai composite in mainland China both falling nearly 1% each.

 

Data Docket: Euro zone economic, industrial and services sentiment surveys for June will be published at 10 a.m. London time, along with a June consumer confidence reading and inflation expectations.

 

Henry’omics:

Waiting for the algorithmic “Pac-man” …

Stocks rose to new highs on Monday; the S&P 500 advanced 0.23%, registering its third straight record close as the Nasdaq gained nearly 1%, posting its fifth positive session in the last six, and also closed at a new high while the Dow pulled back.

June and Q2 are about to end on Wednesday, I’d be leery of leaving chance on the table.

 

Intellia Therapeutics (NTLA) Proposes $400 M Public Offering. NTLA closed up +$44.60 or +50.21% after researchers tested a single dose of gene-editing treatment in patients with transthyretin amyloidosis and polyneuropathy (a disorder caused by the buildup of abnormal protein) … https://www.regmedinvestors.com/articles/11975

 

RegMed/Cell and Gene Therapy Earnings Scorecard Q1/21 LPS Results to date …  https://www.regmedinvestors.com/articles/11628

 

Monday’s evening’s recap: “Gene editing moves the sector followed by an expected offering. It’s the investor against the “machine” with a bit of complacency in today’s sector as Biostage (BSTG) continues to “pump” its way-out from delisting.” … https://www.regmedinvestors.com/articles/11976

  • The Nasdaq closed UP +140.12 points (+0.98%);
  • The IBB closed up +0.15% and XBI closed down -0.60%
  • Sector volume was HIGH with 10 of the 18-upside having higher than the 3-month average volume with LOW volume of 4 of 15-downside having higher than the 3-month average volume;
  • The CBOE Volatility Index (VVIX: INDEX) was up +0.14 points or +0.90% at 15.76
  • Monday’s percentage (%) of the 18-upside were +0.10% (IONS) to +50.21% (NTLA) while the 15-downside ranges from -0.27% (FIXX) to -8.92% (GBT);

Q2/21:

June: 15 positive and 6 negative closes

May:  8 positive, 12 negative closes and 1 holiday

April: 11 negative and 10 positive closes

Q1/21:

  • March: 10 positive, 12 negative and 1 neutral closes
  • February: 9 positive, 10 negative closes and 1 holiday
  • January: 10 positive, 9 negative closes and 1 holiday

 

Companies in my headlights – It’s your decision; I provide an idea and context:

The Biostage (BSTG) - Maintaining Sell – It’s about saying WHAT NEEDS to be written …

Biostage (BSTG) closed down again -$0.02 to $1.23 with 1,177 shares traded after Friday’s -$0.10 to $1.25 with 1,00 shares traded, Thursday’s +$0.10 to $1.35 with 1,920 shares traded, Wednesday’s -$0.05 to $1.25 with 11,915 shares traded and last Tuesday’s +$0.09 to $1.30 with 4,779 shares traded. WHAT role is DST Capital “playing” in these on-going “volume-pumping” pricing “moves” – to keep the company from being de-listed?

Question#1: The REAL question to be ANSWERED is WHO is advising them in ALL of these endeavors and was has been the effect and did/has affected conditions within the company and past issues that STILL remain UNRESOLVED?

MINORITY PUBLIC shareholders are waiting for the specific time, watching and weighing responses to MAINTAIN their RIGHTS.

 

The morning’s indications:

BUY:

Ionis Pharmaceuticals (IONS) closed up +$0.04 to $38.97 and has a positive +$0.58 or +1.49% pre-market indication.

 

SELL from BUY:

Intellia Therapeutics (NTLA) closed up +$44.60 to $133.43 after Friday’s +$1.99 to $88.83, Thursday’s +$3.25 to $86.84, Wednesday’s +$4.68 to $83.59, Tuesday’s -$0.31 to $78.91 and last Monday’s +$3.30 to $79.22 and has -$1.93 or -1.45% pre-market indication after jumping on news and then a $400 offering.

 

SELL into Strength:

Vericel (VCEL) closed up again +$0.41 to $67.81 after Friday’s +1.64 to $67.40, Thursday’s $65.76 and Wednesday’s $64.79 Tuesday’s $61.06 and last Monday’s $61.23 with NO aftermarket indication.

Editas Medicine (EDIT) closed up again +$2.11 to $43.99 after Friday’s +$1.01 to $41.88, Thursday’s +$3.05 to $40.87 Wednesday’s +$0.1.41 to $37.82, Tuesday’s -$0.45 to $36.41 and last Tuesday’s +$0.98 to $36.86 and has a positive +$0.44 or +1% pre-market indication.

CRISPR Therapeutics (CRSP) closed up again +$9.111 to $151.63 after Friday’s +$4.76 to $142.52, Thursday's +$7.20 to $137.88 and Wednesday’s +$1.48 to $130.48 with a positive +$162 or +1.07% aftermarket indication.

 

SELL:

Alnylam Pharmaceuticals (ALNY) closed down -$9.19 or -5.2% to $166.20 and has a negative -$2.95 or -1.77% aftermarket indication because ALNY works on a medicine to treat transthyretin amyloidosis --the disease NTLA is trying to cure in its study.

 

Maintaining SELL:

Homology Medicine (FIXX) closed down -$0.02 to $7.29 and has a negative -$0.44 or -6.04% aftermarket indication.

Cellectis SA (CLLS) closed up again +$0.64 to $16.26 after Friday’s +0.13 to $15.62, Thursday’s $0.69 to $15.49, Wednesday’s +$0.19 to $14.80 and last Tuesday’s +$0.10 to $14.61 and has a negative -$0.28 or -1.72% pre-market indication.

 

The BOTTOM LINE: Cell and gene therapy sector equities are still flying faster by tailwinds however; headwinds and turbulence are ahead - investors should use rallies to book profits.

Notice the dwindling of upside movement and increasing downside numbers: overpast four (4) sessions …

  • Monday closed positive at 18 advancers,15 decliners, 1 flat and 1 acquired;
  • Friday closed positive with 18 advancers, 13 decliners, 3 flat and 1 acquired
  • Thursday closed positive with 28 advancers, 5 decliners, 1 flat and 1 acquired
  • Wednesday positive with 25 advancers, 9 decliners and 1 acquired

I also continue to MAINTAIN, this is a confused sector as sentiment rages and fades, momentum is usurped, fundamentals are being ignored.

When you’re on a roller coaster, the only thing you can be sure of is you’ll end up back where you started

A true contrarian thought …

My focus has always been “warning analysis” … my advice, trim and skim any new highs if one can!” I also see a number of lows that could be in the “pick-up” stock game.

My motto, never leave an investor uninformed about what I know!

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Regulation Analyst Certification ("Reg AC"): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.